Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo syndrome mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is presently no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which pla ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Image guided Planning System for Skull Correction in Children with Craniosynostosis Phase II

    SBC: Kitware, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in live births It results in cranial malformation that can lead to elevated intra cranial pressure brain growth impairment and developmental deficiency The most common treatment option for craniosynostosis is surgery Currently surgical treatment planning of c ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

    SBC: Abcombi Biosciences Inc            Topic: NIAID

    PROJECT SUMMARY Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV strains that are resistant to current antivirals H N underscores the need for new treatment strategies particularly those that modify the host response IAVs ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Pre Clinical Safety and Efficacy of TRB N for the Treatment of Periodontal Disease

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    PROJECT SUMMARY ABSTRACT Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a proprietary chemic ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government